多中心评估:纯内镜下经鼻入路治疗53例嗅神经母细胞瘤
基于法国REFCOR数据库的53例嗅神经母细胞瘤患者,均接受纯内镜下经鼻手术(49%联合颅底切除与修复),5年总生存率87%、无病生存率71%,并发症率18.8%,切缘阳性率26.8%但未影响生存,结论认为纯内镜治疗有效可靠。
要点
- 纯内镜下经鼻入路治疗嗅神经母细胞瘤可行且可靠。
- 5年总生存率87%,无病生存率71%。
- 切缘阳性率26.8%但未显著影响生存。
核心结论
- 纯内镜下治疗在大样本对照系列中显示有效且可靠。
研究设计与样本
- 多中心协作研究,纳入法国REFCOR数据库53例嗅神经母细胞瘤患者(16例T1、8例T2、19例T3、10例T4),均行纯内镜下手术,26例(49%)联合颅底切除与修复,未行外部开颅。
主要发现
- 5年总生存率为87%,无病生存率为71%,平均随访45.4±26.5个月。
- 并发症发生率为18.8%,其中4例为脑膜炎。
- 病理分析显示切缘阳性率为26.8%,多见于硬脑膜和眶骨膜,但未影响总生存或无病生存。
- 预防性颈部照射似乎可降低复发率。
临床怎么用
- 对于嗅神经母细胞瘤,可考虑纯内镜下经鼻入路作为有效治疗方式,必要时联合颅底切除与修复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the particularities of olfactory neuroblastoma (ONB) and the lack of studies on the subject, a multicenter collaborative study was conducted to assess treatment strategy. METHODS: Fifty-three patients with ONB were included from the French Rare Head and Neck Cancer Expert Network (REFCOR) database: 16T1, 8T2, 19T3, and 10T4. All cases were treated endoscopically with skull base removal and repair in 26 cases (49%) and without external craniotomy. RESULTS: The overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% and 71%, respectively, with mean follow-up of 45.4 ± 26.5 months. The complication rate was 18.8% with 4 cases of meningitis. Pathological analysis showed positive margins in 26.8%, notably on the dura-mater and periorbita, without impairment of OS or DFS. Forty-eight patients received adjuvant radiotherapy on T ± N. Ten patients had a recurrence (18.9%). Six patients died of their disease. Prophylactic neck irradiation seemed to reduce the recurrence rate. CONCLUSION: Exclusively endoscopic treatment proved efficient and reliable in a large controlled series.
引用
- de Gabory L, Verillaud B, Rumeau C, et al. Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas. Head Neck. 2018. PMID: 29356209. doi:10.1002/hed.25064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。